Tufts Medicine account plan
Health care provider network
At a glance
Tufts Medicine is a Boston-area nonprofit health system of four acute hospitals, home care and an ACO network, with FY2025 revenue of $2,967.3 million.
Tufts Medicine, Inc. is the Boston-area nonprofit parent of Tufts Medical Center, Lowell General Hospital (Circle Health), MelroseWakefield Healthcare (two acute hospitals), Tufts Medicine Care at Home, the Tufts Medicine Integrated Network and a Cayman captive insurer. In FY2025 (year to September 30, 2025) total revenue was $2,967.3 million, up from $2,639.3 million, and the loss from operations narrowed to $58.6 million from $250.7 million. Patient service revenue of $2,342.4 million came 38% from Medicare, 39% from managed care and 18% from Medicaid. The system is in a financial turnaround on a thin balance sheet, with long-term debt of $894.8 million against net assets of $190.4 million.
Business units
Tufts Medical Center
operating revenue $1,245.7 million for the nine months to June 30, 2026The academic flagship acute care hospital in the greater Boston area, with its physician organization, a nursing home and imaging joint ventures. It is profitable, with an operating margin of 3.9% in the nine months to June 30, 2026, but its physician organization lost $68.1 million.
Circle Health (Lowell General Hospital)
operating revenue $530.3 million for the nine months to June 30, 2026General acute care hospital in Lowell, Massachusetts, with physician practices, a pharmacy and surgical and imaging joint ventures. Its operating margin fell to 2.0% from 6.0% in the nine months to June 30, 2026.
MelroseWakefield Healthcare
operating revenue $188.3 million for the nine months to June 30, 2026Two acute care hospitals north of Boston with physician practices, long-term care and real estate affiliates. It is the weak hospital: revenue fell from $220.3 million and the operating margin was -10.1% in the nine months to June 30, 2026.
Tufts Medicine Care at Home
home health and hospice are 2% of patient service revenueHome health, hospice and homemaker services in Massachusetts and southern New Hampshire.
Tufts Medicine Integrated Network (TMIN)
risk-based contracts $99.4 million of other revenue in FY2025Population-health arm running ACOs and physician networks under commercial risk contracts and Medicare shared savings programmes, with settlements shared with affiliate physicians.
Tufts Medicine Indemnity Company (TMEDIC)
Cayman Islands captive insurer providing professional and general liability and stop-loss cover to the system.
Strategic priorities
- Financial turnaround
- The board chair says the system is entering the next phase of its financial turnaround; the FY2025 deficiency narrowed to $51.6 million from $214.0 million.
- Throughput and clinical growth
- The CFO named access, length of stay and growth of key clinical programs as next priorities in July 2025.
- Payer mix and ambulatory care
- Management aims to shift payer mix and expand the ambulatory setting; outpatient grew to 41% of patient service revenue in FY2025 from 38%.
- Rebuilding the balance sheet
- The plan includes monetizing non-strategic assets; a 30-year energy-as-a-service deal on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
- Value-based care
- The CFO wants to bend the cost curve and move to value-based care, building on TMIN's risk contracts.
Latest results
For the nine months to June 30, 2026 (fiscal Q3 2026), the CHIA filing shows total operating revenue of $2,468.9 million against $2,278.9 million a year earlier. The system operating loss was $79.5 million, an operating margin of -3.2% against -2.2% in the prior year-to-date, and the deficit of revenue over expenses widened to $62.8 million from $47.0 million. Tufts Medical Center improved to a 3.9% margin while MelroseWakefield fell to -10.1% and Lowell General slipped to 2.0%. Cash stood at $62.1 million and long-term debt at $914.5 million at June 30, 2026, with debt service coverage of 0.56.
Investments and deals
- Bond refinancing
- In November 2025 the 8.50% Series E bonds and two smaller series were refinanced into Series F ($30.2 million, 5.50%) and Series G ($154.1 million).
- Energy-as-a-service deal
- A 30-year energy-as-a-service agreement on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
- Lab outreach sale
- Lab outreach testing was sold to Labcorp, involving 600 roles.
- Pharmacy growth
- Specialty and retail pharmacy revenue grew to $355.3 million in FY2025 from $244.2 million.
Challenges and risks
- Operating losses
- The system lost $79.5 million at the operating level in the nine months to June 30, 2026, with a -3.2% margin.
- Thin balance sheet
- Cash was $62.1 million and long-term debt to capitalization 0.92 at June 30, 2026; capex was cut to $23.6 million in FY2025 from $51.5 million.
- Loss-making physician organizations and MelroseWakefield
- The Tufts Medical Center Physician Organization had a -22.8% margin and MelroseWakefield a -10.1% margin in the nine months to June 30, 2026.
- Leadership transition
- CEO Mike Dandorph and CFO Andrew Devoe are stepping down; a national CFO search is under way.
- Cost inflation and payer denials
- The CFO cited post-COVID cost inflation and payer denials, 97-99% of which are overturned on appeal; FEMA COVID grant revenue fell to $10.9 million from $57.4 million.
What leadership says
“we have turned the corner, and we're starting to rebuild the balance sheet”
“While important work remains ahead, we have generated significant momentum and are entering the next phase of our financial turnaround with greater focus, discipline and purpose”
“Our focus remains unchanged: serving our patients and communities, supporting our people, strengthening our financial position and continuing to advance Tufts Medicine's mission to empower people to live their best lives”
Where a supplier can help
- Revenue cycle and denials
- Tied to the payer-denials challenge and the turnaround priority: revenue cycle, pre-authorization and denial-management vendors, including contingency-based offers the CFO has used, address a lever management names.
- Throughput and capacity
- Tied to the throughput priority: patient-flow, scheduling and length-of-stay tools support access and clinical program growth.
- Ambulatory expansion
- Tied to the ambulatory care priority: outpatient facilities, digital front door and ambulatory operations partners fit the shift away from inpatient care.
- Value-based care analytics
- Tied to the value-based care priority and TMIN's risk contracts: population-health and care-coordination analytics support shared-savings performance.
- Cost and asset monetization
- Tied to the thin balance sheet: suppliers offering capital-light or as-a-service models, like the energy deal, match the push to monetize non-strategic assets.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Tufts Medicine?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Tufts Medicine, Inc. and Affiliates – Consolidated Financial Statements and Single Audit Reports, FY ended September 30, 2025
- Tufts Medicine, Inc. is the Boston-area nonprofit parent of Tufts Medical Center, Lowell General Hospital (Circle Health), MelroseWakefield Healthcare (two acute hospitals), Tufts Medicine Care at Home, the Tufts Medicine Integrated Network (TMIN) and a Cayman captive insurer (TMEDIC).
- FY2025 (year to September 30, 2025): total revenue $2,967.3 million, up from $2,639.3 million; patient service revenue $2,342.4 million; other revenue $550.2 million, of which specialty and retail pharmacy $355.3 million.
- Loss from operations narrowed to $58.6 million from $250.7 million; deficiency in revenue over expenses $51.6 million vs $214.0 million; net cash from operations turned positive at $23.5 million (FY2024: $203.9 million used).
- Payer mix of patient service revenue: Medicare 38%, managed care 39%, Medicaid 18%; inpatient 42% and outpatient 41% of patient service revenue (outpatient up from 38%).
- Thin balance sheet: cash $65.4 million, liquidity (cash plus investments) $412.1 million, long-term debt $894.8 million net of current portion, net assets $190.4 million (down from $236.8 million); capex cut to $23.6 million from $51.5 million.
- Costs: salaries and wages $1,353.4 million; purchased services fell to $431.2 million from $492.9 million while supplies and other rose to $832.4 million from $701.2 million.
- Massachusetts 1115 Medicaid Waiver added net $78.8 million (incremental funding $248.3 million less $169.4 million paid assessments); FEMA COVID grant revenue dropped to $10.9 million from $57.4 million.
- After year-end: November 2025 refinancing of the 8.50% Series E bonds and two smaller series into Series F ($30.2 million, 5.50%) and Series G ($154.1 million, 6.375-6.625%); a 30-year energy-as-a-service deal on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
- Audited by Grant Thornton (report dated December 19, 2025, unmodified); federal awards of $55.7 million, one compliance finding on student aid status after the closure of the Lawrence Memorial Hospital School of Nursing.
- CHIA Massachusetts Hospital and Hospital System YTD Report – data through June 30, 2026 (Tufts Medicine entities)
- Massachusetts CHIA year-to-date filing for the nine months to June 30, 2026 (fiscal Q3 2026): Tufts Medicine total operating revenue $2,468.9 million vs $2,278.9 million a year earlier.
- System operating loss $79.5 million and operating margin -3.2% (prior YTD -2.2%); total margin -2.5%; deficit of revenue over expenses $62.8 million (prior YTD $47.0 million).
- Tufts Medical Center is profitable: operating revenue $1,245.7 million (prior YTD $1,073.2 million), operating margin 3.9% (prior YTD 2.3%).
- Lowell General Hospital: operating revenue $530.3 million, operating margin 2.0%, down from 6.0%.
- MelroseWakefield Healthcare is the weak hospital: operating revenue fell to $188.3 million from $220.3 million, operating margin -10.1% (prior YTD 0.8%).
- Physician organizations lose money: Tufts Medical Center Physician Organization operating loss $68.1 million on $298.6 million revenue (-22.8%); Circle Health Physicians -19.7%.
- Balance sheet at June 30, 2026: cash $62.1 million, total net assets $131.9 million, long-term debt $914.5 million; debt service coverage 0.56 and long-term debt to capitalization 0.92.
- Context: the median Massachusetts hospital health system had an operating margin of -1.3% and only 7 of 21 systems had an operating profit.
- Becker's CFO + Revenue Cycle Podcast: Andrew DeVoe, Executive Vice President and CFO of Tufts Medicine
- Andrew DeVoe, EVP and CFO of Tufts Medicine (joined February 2024 to lead the turnaround), on the Becker's CFO + Revenue Cycle podcast, July 2025.
- Says Tufts went from a "$300,000,000 loss run rate" when he started to a monthly profit in April 2025, about fourteen months in: "we have turned the corner".
- Levers: eliminating contract labor, centralized benchmarking that cut almost 1,000 FTEs while growing, fixing the revenue cycle (pre-authorization gaps, Epic tuning).
- Collections per RVU rose from about $68 to about $84; almost $100 million of improvement on one side of the revenue cycle.
- Uses consultants on contingency deals to move fast, as he did at Penn ($400 million of extra cash collected).
- Next priorities: throughput (access, length of stay), growing key clinical programs, a payer mix shift, expanding ambulatory care, and monetizing non-strategic assets to rebuild a weak balance sheet.
- Wants to bend the cost curve and move to value-based care, citing a below-3% cost-of-care growth rate achieved at TriHealth against 6-8% in that market.
- Trends he watches: post-COVID cost inflation, payer denials (97-99% overturned on appeal), and value-based transformation.
- Tufts Medicine CEO, CFO step down amid financial struggles (Healthcare Dive)
- Healthcare Dive, August 6, 2026: Tufts Medicine CEO Mike Dandorph and CFO Andrew Devoe are stepping down.
- Dandorph, CEO since January 2020, stays through the end of fiscal 2026 (September 30); COO Phil Okala then becomes chief executive.
- Greg Kruse, vice president of strategic operations and analytics intelligence, takes over budget planning and some financial services while a national CFO search runs.
- Board chair Phil Lembo: the system is "entering the next phase of our financial turnaround with greater focus, discipline and purpose".
- Okala: priorities include "strengthening our financial position".
- Background cited: 174 layoffs in 2024 (about 1% of the workforce), 70 administrative layoffs in 2023, sale of lab outreach testing to Labcorp (600 roles), FY2025 net loss of $51.6 million vs $214 million.
Questions about Tufts Medicine
What is Tufts Medicine?
A Boston-area nonprofit health system that owns Tufts Medical Center, Lowell General Hospital, MelroseWakefield Healthcare, a home care and hospice business, an ACO network and a captive insurer.
What is Tufts Medicine's revenue?
Total revenue was $2,967.3 million in FY2025 (year to September 30, 2025). Operating revenue was $2,468.9 million for the nine months to June 30, 2026.
Who leads Tufts Medicine?
Mike Dandorph is CEO through the end of fiscal 2026, after which COO Phil Okala becomes chief executive. Phil Lembo chairs the board.
Is Tufts Medicine profitable?
No. It reported a loss from operations of $58.6 million in FY2025 and an operating loss of $79.5 million in the nine months to June 30, 2026, though Tufts Medical Center itself is profitable.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)